Cancer-related fatigue: state of the science

SA Mitchell - PM&R, 2010 - Elsevier
Cancer-related fatigue (CRF) is a disabling and distressing symptom that is highly prevalent
across the cancer continuum from a patient's diagnosis and treatment through survivorship …

Cancer-related fatigue: state of the science.

SA Mitchell - PM & R: the Journal of Injury, Function, and …, 2010 - europepmc.org
Cancer-related fatigue (CRF) is a disabling and distressing symptom that is highly prevalent
across the cancer continuum from a patient's diagnosis and treatment through survivorship …

Cancer-Related Fatigue: State of the Science

SA Mitchell - PM&R, 2010 - infona.pl
Cancer-related fatigue (CRF) is a disabling and distressing symptom that is highly prevalent
across the cancer continuum from a patient's diagnosis and treatment through survivorship …

[引用][C] Cancer-Related Fatigue: State of the Science

SA Mitchell - PM&R, 2010 - cir.nii.ac.jp

Cancer-Related Fatigue: State of the Science

SA Mitchell - PM & R (New York), 2010 - hero.epa.gov
Cancer-related fatigue (CRF) is a disabling and distressing symptom that is highly prevalent
across the cancer continuum from a patient's diagnosis and treatment through, survivorship …

Cancer-Related Fatigue: State of the Science

SA Mitchell - PM & R: Journal of Injury, Function & …, 2010 - search.ebscohost.com
Abstract: Cancer-related fatigue (CRF) is a disabling and distressing symptom that is highly
prevalent across the cancer continuum from a patient''s diagnosis and treatment through …

Cancer-related fatigue: state of the science

SA Mitchell - PM & R: the journal of injury, function, and …, 2010 - pubmed.ncbi.nlm.nih.gov
Cancer-related fatigue (CRF) is a disabling and distressing symptom that is highly prevalent
across the cancer continuum from a patient's diagnosis and treatment through survivorship …

Cancer‐Related Fatigue: State of the Science

SA Mitchell - PM&R, 2010 - Wiley Online Library
Cancer‐related fatigue (CRF) is a disabling and distressing symptom that is highly prevalent
across the cancer continuum from a patient's diagnosis and treatment through survivorship …